Clinical Studies

Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against  several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second drug, Encequidar, which improves this issue of poor absorption. Preclinical studies have demonstrated safety in dogs, making Oraxol an intriguing choice for further study in cancer-bearing dogs. The data collected from this study will help to inform future studies in the treatment of canine hemangiosarcoma, a common and aggressive cancer in dogs.

Eligibility criteria

Dogs diagnosed with cancer of any kind

Dogs weighing between 10kg and 45kg

Dogs who haven’t received chemotherapy within 14 days of study entry

Dogs with no significant kidney disease

Dogs with no significant liver disease

Interested?

Enroll or request more information below